Annovis Bio (ANVS) Stock Price, News & Analysis

Company Overview

Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease. The company’s research centers on treatments designed to address the underlying mechanisms that contribute to the accumulation of multiple neurotoxic proteins in the brain.

Annovis’ lead drug candidate is buntanetap, formerly known as ANVS401. The orally administered small-molecule therapy is being developed to reduce the production of several neurotoxic proteins, including amyloid beta, tau and alpha-synuclein, which are associated with neurodegenerative disorders. The company has evaluated buntanetap in clinical studies involving patients with Alzheimer’s and Parkinson’s disease.

Annovis Bio was founded in 2008 and is headquartered in Berwyn, Pennsylvania. The company’s operations are focused on research and clinical development, with its programs subject to ongoing evaluation for safety and effectiveness. Maria Maccecchini, Ph.D., the company’s founder, serves as president and chief executive officer.

Key Stats

• Today's Range: $1.14 to $1.24
• 50-Day Range: $1.08 to $1.89
• 52-Week Range: $1.04 to $5.50
• Volume: 521,870 shs
• Average Volume: 955,451 shs
• Market Capitalization: $52.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Hold

Annovis Bio Stock Analysis - MarketRank™

Annovis Bio scored higher than 37% of companies evaluated by MarketBeat, and ranked 701st out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Hold

Consensus Rating

Annovis Bio has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Annovis Bio has a consensus price target of $12.00, representing about 879.6% upside from its current price of $1.23.

Amount of Analyst Coverage

Annovis Bio has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Annovis Bio are expected to grow in the coming year, from ($1.32) to ($0.54) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Annovis Bio is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Annovis Bio is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Annovis Bio has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.43% of the float of Annovis Bio has been sold short.

Short Interest Ratio / Days to Cover

Annovis Bio has a short interest ratio ("days to cover") of 5.95.

Change versus previous month

Short interest in Annovis Bio has recently decreased by 2.09%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Annovis Bio does not currently pay a dividend.

Dividend Growth

Annovis Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

MarketBeat Follows

Only 4 people have added Annovis Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Annovis Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

15.92% of the stock of Annovis Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

15.83% of the stock of Annovis Bio is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 10/09/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSE:ANVS
• CIK: 1477845
• Web: www.annovisbio.com
• Phone: (484) 875-3192
• Fax: N/A
• Employees: 7
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Annovis Bio: $12.00
• High Price Target: $17.00
• Low Price Target: $7.00
• Potential Upside/Downside: +879.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.79)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$28.85 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -685.98%
• Return on Assets: -258.77%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.47
• Quick Ratio: 3.47

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.64 per share
• Price / Book: 1.91

Miscellaneous

• Outstanding Shares: 42,680,000
• Free Float: 35,885,000
• Market Cap: $52.28 million
• Optionable: Optionable
• Beta: 1.23